Gene Therapy for Spinal Muscular Atrophy| A Pipeline Analysis Report 2018| Technavio

LONDON--(BUSINESS WIRE)-- Technavio has announced their latest pipeline analysis report on the gene therapy for spinal muscular atrophy. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat gene therapy for spinal muscular atrophy.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for spinal muscular atrophy, i ...

Technavio has published a new report on the drug development pipeline for spinal muscular atrophy, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Gene therapy for spinal muscular atrophy: Market overview

Spinal muscular atrophy is a genetic condition that causes weakening of the muscles and results in the loss of movement in the affected individual. It mostly occurs in neonates and progress with time. Persons affected with SMA have a breakdown of nerve cells in the brain and the spinal cord. As a result, the brain stops sending the signals that control the muscle movement to the spinal cord. The muscle shrink and get weak, thus making it tough for the individual to control the head movement, sitting without any external support, and walking.

According to a senior market research analyst at Technavio for research on infectious and rare diseases, “There are no known cures for the disease; however, there are multiple treatment options available for SMA, which can help improve the symptoms and live longer.”

Gene therapy for spinal muscular atrophy: Segmentation analysis

This pipeline analysis report segments the gene therapy for spinal muscular atrophy market based on therapies employed that includes monotherapy, RoA (intravenous and intrathecal), therapeutic modalities (gene), targets for drugs under development (SMN1 gene and SMN2 gene), MoA (gene therapy), drugs under development (pre-clinical, phase I, and phase III), and recruitment status (recruiting, not yet recruiting, and undisclosed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


View source version on


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200


Source: Technavio Research


Back to news